Clinical trial • Phase I | Phase III • Oncology
Clinical trial in Glioblastoma (WHO grade IV glioma)
Phase I | Phase III trial for Glioblastoma (WHO grade IV glioma). 15 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Glioblastoma (WHO grade IV glioma)
- Trial Stage
- Phase I | Phase III
Key dates
- Initial CTIS Submission Date
- 10-07-2024
- First CTIS Authorization Date
- 08-08-2024
Trial design
Phase I | Phase III trial across 7 sites in Germany.
- Target Sample Size
- 15
Recruitment
- Planned Sample Size
- 15
- Recruitment Window Months
- 34
Geography
- Total Number Of Sites
- 7
- Total Number Of Participants
- 15
Germany
- Earliest CTIS Part Ii Submission Date
- 19-06-2024
- Latest Decision Or Authorization Date
- 08-08-2024
- Processing Time Days
- 50
- Number Of Sites
- 7
- Number Of Participants
- 15
Sites
- Site Name
- Universitaetsklinikum Tuebingen AöR
- Department Name
- Neurologie mit Interdisziplinärem Schwerpunkt Neuroonkologie
- Principal Investigator Name
- Ghazaleh Tabatabai
- Principal Investigator Email
- ghazaleh.tabatabai@med.uni-tuebingen.de
- Contact Person Name
- Ghazaleh Tabatabai
- Contact Person Email
- ghazaleh.tabatabai@med.uni-tuebingen.de
- Site Name
- Universitaetsklinikum Essen AöR
- Department Name
- Klinische Neuroonkologie
- Principal Investigator Name
- Sied Kebir
- Principal Investigator Email
- sied.kebir@uk-essen.de
- Contact Person Name
- Sied Kebir
- Contact Person Email
- sied.kebir@uk-essen.de
- Site Name
- Universitaetsklinikum Mannheim GmbH
- Department Name
- Neurologische Klinik
- Principal Investigator Name
- Michael Platten
- Principal Investigator Email
- m.platten@Dkfz-Heidelberg.de
- Contact Person Name
- Michael Platten
- Contact Person Email
- m.platten@Dkfz-Heidelberg.de
- Site Name
- Goethe University Frankfurt
- Department Name
- Dr. Senckenbergisches Institut für Neuroonkologie
- Principal Investigator Name
- Michael Ronellenfitsch
- Principal Investigator Email
- michael.ronellenfitsch@unimedizin-ffm.de
- Contact Person Name
- Michael Ronellenfitsch
- Contact Person Email
- michael.ronellenfitsch@unimedizin-ffm.de
- Site Name
- Universitaetsklinikum Heidelberg AöR
- Department Name
- Neurologische Klinik
- Principal Investigator Name
- Antje Wick
- Principal Investigator Email
- antje.wick@med.uni-heidelberg.de
- Contact Person Name
- Antje Wick
- Contact Person Email
- antje.wick@med.uni-heidelberg.de
- Site Name
- Universitaetsklinikum Bonn AöR
- Department Name
- Sektion Klinische Neuroonkologie
- Principal Investigator Name
- Ulrich Herrlinger
- Principal Investigator Email
- ulrich.herrlinger@ukb.uni-bonn.de
- Contact Person Name
- Ulrich Herrlinger
- Contact Person Email
- ulrich.herrlinger@ukb.uni-bonn.de
- Site Name
- Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
- Department Name
- Klinik und Poliklinik für Neurochirurgie
- Principal Investigator Name
- Dietmar Krex
- Principal Investigator Email
- Dietmar.Krex@uniklinikum-desden.de
- Contact Person Name
- Dietmar Krex
- Contact Person Email
- Dietmar.Krex@uniklinikum-desden.de
Sponsor
Primary sponsor
- Full Name
- Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
- Organisation Type
- Laboratory/Research/Testing facility
- Country Of Registered Address
- Germany
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)